Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03330405
Title Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Pfizer
Indications

progesterone-receptor positive breast cancer

transitional cell carcinoma

ovarian cancer

prostate cancer

estrogen-receptor positive breast cancer

Advanced Solid Tumor

lung non-small cell carcinoma

triple-receptor negative breast cancer

Therapies

Avelumab + Talazoparib

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.